Dystrophic Epidermolysis Bullosa Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting dystrophic epidermolysis bullosa clinical trials across 7 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Redwood City, California, United States, Rancho Santa Margarita, California, United States, Coral Gables, Florida, United States. Updated daily from ClinicalTrials.gov.


Dystrophic Epidermolysis Bullosa Trials at a Glance

8 actively recruiting trials for dystrophic epidermolysis bullosa are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Redwood City, Rancho Santa Margarita, and Coral Gables. Lead sponsors running dystrophic epidermolysis bullosa studies include Krystal Biotech, Inc., CHU de Quebec-Universite Laval, and Anterogen Co., Ltd..

Browse dystrophic epidermolysis bullosa trials by phase

About Dystrophic Epidermolysis Bullosa Clinical Trials

Looking for clinical trials for Dystrophic Epidermolysis Bullosa? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dystrophic Epidermolysis Bullosa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dystrophic Epidermolysis Bullosa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosaEpidermolysis BullosaDystrophic Epidermolysis Bullosa+1 more
M. Peter Marinkovich8 enrolled1 locationNCT06834035
Recruiting
Phase 1Phase 2

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

Recessive dystrophic epidermolysis bullosaEpidermolysis Bullosa Dystrophica, RecessiveRDEB
CHU de Quebec-Universite Laval9 enrolled1 locationNCT07193134
Recruiting
Phase 3

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosaDystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis Bullosa+1 more
Krystal Biotech, Inc.16 enrolled5 locationsNCT07016750
Recruiting
Phase 2

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Dystrophic Epidermolysis BullosaEpidermolysis Bullosa (EB)Junctional Epidermolysis Bullosa
Xinnate AB32 enrolled6 locationsNCT06594393
Recruiting
Phase 1Phase 2

Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

Wound HealDystrophic Epidermolysis Bullosa
Isfahan University of Medical Sciences20 enrolled1 locationNCT07230223
Recruiting
Phase 1Phase 2

MSC EVs in Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa
Aegle Therapeutics8 enrolled3 locationsNCT04173650
Recruiting
Phase 2

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa
Anterogen Co., Ltd.6 enrolled1 locationNCT05157958
Recruiting

Long-Term Follow-up Protocol

Recessive dystrophic epidermolysis bullosaDystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.50 enrolled3 locationsNCT04917887